The creation, development and diffusion of the LARCG- latin american renal cancer group

Zéqui, Stênio de Cássio; Clavijo, Diego Abreu

doi:10.1590/s1677-5538.ibju.2017.01.02

Cited by 7 publications

(5 citation statements)

References 1 publication

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The cohort was derived from an international collaborative study group of large academic referral centers in Latin America and the United States. 9 The Institutional Review Boards approved the study, and all patients signed an informed consent form to participate. Based on tissue availability, tissue microarrays (TMAs) were prepared from archival formalin-fixed paraffin-embedded specimens from 1017 cases of nonmetastatic, surgically treated ccRCC.…”

Section: Patient Selection and Sample Collectionmentioning

confidence: 99%

Prognostic value of PD-L1 expression for surgically treated localized renal cell carcinoma: implications for risk stratification and adjuvant therapies

Chipollini

Costa

Cunha

et al. 2019

Therapeutic Advances in Urology

Self Cite

View full text Add to dashboard Cite

Background:We aimed to evaluate the prognostic role of programmed-death receptor ligand (PD-L1) in a multinational cohort of patients with localized renal cell carcinoma (RCC).Methods:Formalin-fixed paraffin-embedded blocks of 1017 patients from the Latin American Renal Cancer Group were analyzed. Tissue microarrays were immunostained for PD-L1 using a commercially available monoclonal antibody. Expression of PD-L1 in ⩾5% tumor cells was considered positive. PD-1 expression in immune cells was also assessed. All cases were reviewed twice based on antibody expression and compared with a positive control. Cox proportional hazard regression models were used to identify predictors of recurrence-free survival (RFS) and overall survival (OS).Results:A total of 738 cases with complete follow up met criteria. Median age was 57 [interquartile range (IQR): 49–64] years, and median follow up was 34 (IQR: 15–62.9) months. Median tumor size was 5 cm (IQR: 3.0–7.5 cm). Approximately 8.2% and 7.6% of tumors were PD-L1 and programmed cell-death 1 (PD-1) positive, respectively. PD-L1 and PD-1 positivity were significantly associated with higher tumor stage (both p < 0.001), and presence of tumor necrosis and lymphovascular multivariable analyses; PD-L1 positivity was found as a predictor of worse RFS [hazard ratio (HR) = 2.08, p = 0.05] and OS (HR = 2.61, p = 0.02).Conclusions:PD-L1 positivity was significantly associated with worse outcomes for patients with localized RCC at intermediate follow up. This marker may help stratify patients for stricter surveillance after surgical treatment and provide a basis for checkpoint-inhibitor therapy in the adjuvant setting.

show abstract

Section: Patient Selection and Sample Collectionmentioning

confidence: 99%

Prognostic value of PD-L1 expression for surgically treated localized renal cell carcinoma: implications for risk stratification and adjuvant therapies

Chipollini

Costa

Cunha

et al. 2019

Therapeutic Advances in Urology

Self Cite

View full text Add to dashboard Cite

show abstract

“…This is a retrospective comparative study of the database of patients with renal tumors from the Latin American Renal Cancer Group (LARCG) 7 . It comprised data from 3656 patients who underwent surgery for RCC from 1990 to 2015 in 28 centers from eight Latin American countries.…”

Section: Methodsmentioning

confidence: 99%

Characteristics and Surgical Outcomes in Very Elderly Patients (>-75 years) with Renal Cell Carcinoma: Data from the Latin American Renal Cancer Group

Garza-Gangemi

Castillejos-Molina

Gueglio

et al. 2021

RIC

View full text Add to dashboard Cite

Background: The incidence of renal cell carcinoma (RCC) is increasing globally due to an aging population and widespread use of imaging studies. Objective: The aim of this study was to describe the characteristics and perioperative outcomes of RCC surgery in very elderly patients (VEP), ≥ 75 years of age. Methods: This is a retrospective comparative study of 3656 patients who underwent the treatment for RCC from 1990 to 2015 in 28 centers from eight Latin American countries. We compared baseline characteristics as well as clinical and perioperative outcomes according to age groups (<75 vs. ≥75 years). Surgical complications were classified with the Clavien-Dindo score. We performed logistic regression analysis to identify factors associated with perioperative complications. Results: There were 410 VEP patients (11.2%). On bivariate analysis, VEP had a lower body mass index (p < 0.01) and higher ASA score (ASA >2 in 26.3% vs. 12.4%, p < 0.01). There was no difference in performance status and clinical stage between the study groups. There were no differences in surgical margins, estimated blood

show abstract

“…A total of 220 patients who underwent radical or partial nephrectomy at two South American centres were evaluated between 1989 and 2009. Both institutions are members of the LARCG (Latin American Renal Cancer Group) [ 16 ], and clinical data were obtained from their medical records. The pathological data were reviewed and standardised by a single experienced pathologist (IWC), and the most representative areas of the tumour were selected for the construction of a tissue microarray (TMA).…”

Section: Methodsmentioning

confidence: 99%

Tissue Expression of Erythropoietin Predicts Survival Rates in Clear Cell Renal Cell Carcinoma

Ferreira

Costa

Clavijo

et al. 2017

KCA

Self Cite

View full text Add to dashboard Cite

Objective:To evaluate immunohistochemical erythropoietin (EPO) expression in clear cell renal cell carcinoma (ccRCC), its association with major clinicopathological variables and its prognostic impact.Methods:A total of 220 patients with renal cell carcinoma (RCC) surgically treated between 1989 and 2009 were evaluated in this multi-institutional study. All the cases were reviewed by a single pathologist and the immunohistochemical reactivity to EPO was analysed using tissue microarray.Results:A total of 176 patients with ccRCC were considered, with an average of 48 months of follow-up. Of the tumours evaluated, 47 (26.7%) were negative for EPO expression, and 129 (73.3%) were positive. EPO expression was associated with incidental tumour (p = 0.016), tumour size (p = 0.015), Karnofsky Performance Score (KPS) (p = 0.016), blood transfusion (p = 0.009) and adrenal involvement (p = 0.038). The median ages of the patients with positive and negative EPO expression were 56.2 years and 66.6 years. Immunohistochemical EPO expression affected overall survival (OS) and disease-specific survival (DSS) rates. The DSS rates of the patients whose tissue was positive and negative for EPO expression were 85.3% and 76.1%, respectively (p = 0.044). In a multivariate analysis, the absence of EPO expression proved to be a bad prognostic factor and negatively affected the OS (p < 0.001) and DSS (p < 0.001) rates.Conclusion:The absence of tumour EPO expression is an independent predictive factor with a negative effect on survival rates. The use of EPO as possible marker in the management of ccRCC patients requires further studies and a better understanding of the role of EPO in tumour biology.

show abstract

The creation, development and diffusion of the LARCG- latin american renal cancer group

Cited by 7 publications

References 1 publication

Prognostic value of PD-L1 expression for surgically treated localized renal cell carcinoma: implications for risk stratification and adjuvant therapies

Prognostic value of PD-L1 expression for surgically treated localized renal cell carcinoma: implications for risk stratification and adjuvant therapies

Characteristics and Surgical Outcomes in Very Elderly Patients (>-75 years) with Renal Cell Carcinoma: Data from the Latin American Renal Cancer Group

Tissue Expression of Erythropoietin Predicts Survival Rates in Clear Cell Renal Cell Carcinoma

Contact Info

Product

Resources

About